Clinical Trial Update: Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating avatrombopag for thrombocytopenia in pediatric patients with immune thrombocytopenia for at least 6 months completed; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Avatrombopag (avatrombopag)

Snippet

Sponsor: Sobi, Inc. | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2025-01-17